Category Archives: Obviousness-Teaching Away

DC finding Actavis did not show Tris’ liquid formulation/blood concentration claims obvious affirmed

Tris Pharma, Inc. v. Actavis Laboratories FL, Inc. Docket No. 2021-1495 (https://cafc.uscourts.gov/opinions-orders/21-1495.OPINION.7-7-2022_1974736.pdf) (Non-precedential) MOORE, CHEN, HUGHES July 7, 2022 Brief Summary:   DC decision following remand finding Actavis did not show Tris’ claims obvious affirmed (e.g., “unexpected result”, long-felt unmet … Continue reading

Posted in Generics / ANDA, Obviousness, Obviousness (Secondary Considerations), Obviousness-Teaching Away | Leave a comment

IPR decision finding obviousness and denying entry of amended claims for lack of written description affirmed

Hoyt Augustus Fleming v. Cirrus Design Corporation Docket No. 2021-1561 (IPR2019-01566) (https://cafc.uscourts.gov/opinions-orders/21-1561.OPINION.3-10-2022_1919730.pdf) LOURIE, HUGHES, STOLL March 10, 2022 Brief Summary:  PTAB IPR FWD finding parachute systems claims obvious and denial of entry of amended claims for lacking written description affirmed. … Continue reading

Posted in Inter Parties Review (IPR), IPR, Obviousness (Secondary Considerations), Obviousness-Teaching Away, Written description | Leave a comment

DC decision finding Adapt’s naloxone formulations obvious affirmed

Adapt Pharma, Inc. et al. v. Teva Pharmaceuticals USA, Inc. et al. Docket No. 2020-2106 (https://cafc.uscourts.gov/opinions-orders/20-2106.OPINION.2-10-2022_1906561.pdf) NEWMAN (D), PROST, STOLL February 10, 2021 Brief Summary:  DC decision finding Adapt’s naloxone formulations obvious affirmed. Summary:  Adapt appealed DC final judgment finding … Continue reading

Posted in Generics / ANDA, Obviousness, Obviousness (Secondary Considerations), Obviousness-Teaching Away | Leave a comment

IPR obviousness decisions reversed for lacking a proper explanation and improperly considering the commercial sales evidence

Chemours Company FC, LLC v. Daikin Industries, Ltd. et al. (USPTO as Intervenor) Docket No. 2020-1289, -1290 (IPR2018-00992, -00993) (http://www.cafc.uscourts.gov/sites/default/files/opinions-orders/20-1289.OPINION.7-22-2021_1808187.pdf) NEWMAN, DYK, REYNA July 22, 2021 Brief Summary:  Board obviousness IPR decisions reversed for lacking a proper explanation and improperly … Continue reading

Posted in Inter Parties Review (IPR), IPR, Obviousness, Obviousness (Secondary Considerations), Obviousness-Teaching Away | Leave a comment

Board IPR FWD obviousness findings affirmed (e.g., no teaching away)

Columbia University v. Illumina, Inc. Docket No. 2019-2302-5, -2452 (IPR2019-00291, -00318, -00322, -00385, -00797) (http://www.cafc.uscourts.gov/sites/default/files/opinions-orders/19-2302.OPINION.2-1-2021_1726127.pdf) LOURIE, O’MALLEY, REYNA February 1, 2021 (Non-Precedential) Brief Summary:  IPR obviousness decisions affirmed (e.g., no teaching away). Summary:  Columbia appealed two IPR final written decisions … Continue reading

Posted in Inter Parties Review (IPR), IPR, Obviousness, Obviousness-Teaching Away | Leave a comment

Board IPR FWD remanded regarding reasonable expectation of success

KeyNetik, Inc. v. Samsung Electronics Co., Ltd. Docket No. 2020-1271 (IPR2018-00986) (http://www.cafc.uscourts.gov/sites/default/files/opinions-orders/20-1271.OPINION.1-27-2021_1723945.pdf) DYK, CLEVENGER, O’MALLEY January 27, 2021 (Non-Precedential) Brief Summary:  IPR final written decision remanded for finding on reasonable expectation of success (“The Board erred in assigning no burden … Continue reading

Posted in Claim Construction, Inter Parties Review (IPR), IPR, Obviousness, Obviousness-Teaching Away | Leave a comment

“Substantial risk of future infringement” provides standing for IPR appeal; non-obviousness conclusion vacated and remanded

General Electric Company v. Raytheon Technologies Corporation Docket No. 2019-1319 (IPR2017-00428) (http://www.cafc.uscourts.gov/sites/default/files/opinions-orders/19-1319.OPINION.12-28-2020_1707556.pdf) LOURIE, REYNA, HUGHES December 23, 2020 Brief Summary:  GE found to have standing due to a substantial risk of future infringement”; Board finding of no obviousness vacated and … Continue reading

Posted in Appeal, Obviousness, Obviousness-Teaching Away, Uncategorized | Leave a comment

IPR decision finding Anacor’s KERYDIN® patents invalid for obviousness affirmed

Anacor Pharmaceuticals, Inc. v. Flatwing Pharmaceuticals, LLC Docket No. 2019-2264-2267 (IPR2018-00168-00171, -01358-01361) PROST, NEWMAN (D), HUGHES August 27, 2020 (Non-precedential) Brief Summary: IPR decisions finding Anacor’s tavaborole (5%) (KERYDIN®) patents invalid for obviousness affirmed (e.g., “concentration is a result-effective variable”). … Continue reading

Posted in Inter Parties Review (IPR), IPR, Obviousness, Obviousness-Teaching Away | Leave a comment

IPR obviousness decision vacated and remanded for insufficient explanation

Alacritech, Inc. v. Intel Corp., et al. Docket No. 2019-1467, -1468 (IPR2017-01409-10, -01736-7, IPR2018-00338-9) MOORE, CHEN, STOLL July 31, 2020 Brief Summary: IPR obviousness decision vacated and remanded as Board’s explanation did not “articulate a satisfactory explanation for its action”. … Continue reading

Posted in Inter Parties Review (IPR), IPR, Obviousness, Obviousness-Teaching Away | Leave a comment

Non-obviousness finding for Relistor® OB-listed formulation patent reversed due to structural and functional similarity to prior art compounds

Valeant Pharm. Int., Salix Pharm., Inc. et al. v. Mylan Pharm. Inc., et al., Actavis LLC Docket No. 2018-2097 LOURIE, REYNA, HUGHES April 8, 2020 Brief Summary: DC grant of SJ of non-obviousness of OB formulation patent reversed and remanded … Continue reading

Posted in Generics / ANDA, Obviousness, Obviousness (Secondary Considerations), Obviousness-Teaching Away, Summary Judgment | Leave a comment